Trials / Conditions / Metastatic Ovarian Carcinoma

Metastatic Ovarian Carcinoma

20 registered clinical trials studyying Metastatic Ovarian Carcinoma — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Prediction of Ovarian Cancer Histotypes and Surgical Outcome NCT07057167	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	—
Recruiting	A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NCT06586957	NiKang Therapeutics, Inc.	Phase 1
Terminated	A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NCT06264921	NiKang Therapeutics, Inc.	Phase 1
Recruiting	CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Pati NCT05733000	Northwestern University	Phase 2
Recruiting	First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patien NCT05759923	Molecure S.A.	Phase 1
Recruiting	Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Pa NCT05092373	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide NCT05075993	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fa NCT04673448	University of Washington	Phase 1
Recruiting	Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With A NCT04811703	Hospices Civils de Lyon	Phase 1
Recruiting	Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations NCT04550494	National Cancer Institute (NCI)	Phase 2
Withdrawn	Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer NCT04498520	Pamela Munster	Phase 1
Completed	Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prost NCT04703920	University of Michigan Rogel Cancer Center	Phase 1
Recruiting	PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorecta NCT04329494	City of Hope Medical Center	Phase 1
Suspended	Paclitaxel Therapeutic Drug Monitoring in Cancer Patients NCT03987555	Wake Forest University Health Sciences	—
Terminated	Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Ca NCT03610490	M.D. Anderson Cancer Center	Phase 2
Completed	Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With NCT03508570	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY NCT02650986	Roswell Park Cancer Institute	Phase 1 / Phase 2
Active Not Recruiting	Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ova NCT02627443	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer NCT02298959	National Cancer Institute (NCI)	Phase 1